HC Wainwright Reaffirms “Buy” Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 423.01% from the company’s previous close.

InflaRx Trading Down 1.9 %

InflaRx stock traded down $0.03 during mid-day trading on Monday, reaching $1.53. The company’s stock had a trading volume of 10,861 shares, compared to its average volume of 153,312. InflaRx has a twelve month low of $1.17 and a twelve month high of $2.10. The business has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.51. The firm has a market cap of $90.06 million, a price-to-earnings ratio of -1.42 and a beta of 1.57.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.04 million. InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. On average, equities analysts expect that InflaRx will post -0.98 EPS for the current fiscal year.

Institutional Trading of InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC boosted its stake in InflaRx (NASDAQ:IFRX) by 2.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the period. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent SEC filing. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.